Table 1 Baseline characteristics
CTRCD (n = 13) | No CTRCD (n = 59) | p value | |
|---|---|---|---|
Age (years) | 47.2 ± 7.7 | 49.2 ± 8.8 | 0.471 |
Hypertension (%) | 2 (15.4) | 10 (16.9) | 1.000 |
ACEi or ARB use (%) | 1 (7.7) | 6 (10.2) | 0.629 |
Beta-blocker use (%) | 0 (0.0) | 3 (5.1) | 0.545 |
Diabetes mellitus (%) | 1 (7.7) | 4 (6.8) | 1.000 |
Dyslipidemia (%) | 2 (15.4) | 5 (8.5) | 0.602 |
Smoking (%) | 1 (7.7) | 2 (3.4) | 0.455 |
BMI (kg/m2) | 24.9 ± 4.5 | 23.8 ± 3.9 | 0.412 |
Epirubicin (%) | 5 (38.5) | 29 (49.2) | 0.485 |
Epirubicin dose (mg/m2) | 336.0 ± 68.4 | 314.5 ± 88.4 | 0.610 |
Doxorubicin (%) | 5 (38.5) | 16 (27.1) | 0.504 |
Doxorubicin dose (mg/m2) | 304.8 ± 38.3 | 266.6 ± 32.0 | 0.038 |
Cyclophosphamide (%) | 8 (61.5) | 38 (64.4) | 1.000 |
Cyclophosphamide dose (mg/m2) | 2550.0 ± 424.3 | 2460.0 ± 222.8 | 0.388 |
Docetaxel (%) | 4 (30.8) | 19 (32.2) | 1.000 |
Docetaxel dose (mg/m2) | 337.5 ± 75.0 | 331.6 ± 150.7 | 0.940 |
Radiation therapy (%) | 7 (53.8) | 27 (45.8) | 0.597 |
Radiation dose (cGy) | 5754.9 ± 398.8 | 5628.4 ± 362.3 | 0.426 |